4-(羟基甲基)-7-甲基-8-[3-甲基-3-(3-甲基丁基)环氧乙烷-2-基]-9H-咔唑-1,6-二醇 | 146935-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-(羟基甲基)-7-甲基-8-[3-甲基-3-(3-甲基丁基)环氧乙烷-2-基]-9H-咔唑-1,6-二醇
• 英文名称: (-)-epocarbazolin A
• 英文别名: Epocarbazolin A；4-(hydroxymethyl)-7-methyl-8-[3-methyl-3-(3-methylbutyl)oxiran-2-yl]-9H-carbazole-1,6-diol
• CAS: 146935-39-9
• 化学式: C₂₂H₂₇NO₄
• 分子量: 369.461
• InChiKey: JFHJFCCMTNIENN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  89
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  [1,6-Bis-(tert-butyl-diphenyl-silanyloxy)-8-((E)-2,5-dimethyl-hex-1-enyl)-7-methyl-9H-carbazol-4-yl]-methanol 在 四丁基硫酸氢铵 4-二甲氨基吡啶 、 Oxone 、 Chiral ketone 、 四丁基氟化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 正己烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 4-(羟基甲基)-7-甲基-8-[3-甲基-3-(3-甲基丁基)环氧乙烷-2-基]-9H-咔唑-1,6-二醇
  参考文献：
  名称：

  First total synthesis of (±)-epocarbazolin A and epocarbazolin B, and asymmetric synthesis of (−)-epocarbazolin A via Shi epoxidation

  摘要：

  Epoxidation of the trisilyl-protected carbazomadurins A and B with dimethyldioxirane followed by desilylation provides a simple route to racemic epocarbazolin A and a non-diastereo selective access to epocarbazolin B. The Shi epoxidation has been applied to an asymmetric synthesis of the non-natural (-)-epocarbazolin A. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.06.095

文献信息

• Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas
  申请人：Claesson Hans-Erik

  公开号：US20080081835A1

  公开（公告）日：2008-04-03

  The invention relates to the use of an inhibitor of the biosynthesis and/or function of LTB 4 for the manufacture of a medicament for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), B-prolymphocytic leukemia (B-PLL) or B-cell lymphoma. Preferably, the inhibitor of the biosynthesis and/or function of LTB 4 is the inhibitor of 5-LO BWA4C or the inhibitor of FLAP MK-886.
• Method and composition for treating inflammatory disorders
  申请人：Pereswetoff-Morath Lena

  公开号：US20090220583A1

  公开（公告）日：2009-09-03

  There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.
• Method and Composition for Treating Inflammatory Disorders
  申请人：Meda AB

  公开号：US20160166508A1

  公开（公告）日：2016-06-16

  There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.